3. Read LaRosa, J.C. et al., (2007) Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). The American Journal of Cardiology, 100(5):74752. . Interpret figure 1 in light of table 1 and the figures 2 and 3 of the article 1 that you read previously. Specifically, what can we say regarding the causal effect of achieved LDL on cardiovascular events. . In the discussion (page 751, left column, 3rd full paragraph), the authors note: "This suggests that the observed benefit on major cardiovascular events in TNT is more closely related to achieved on-treatment LDL cholesterol levels than drug dose per se." (Note that by "covaried for" the authors mean "adjusted for.") Comment on whether this claim is justified by the data